Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
Advaxis, Inc.
National Institutes of Health Clinical Center (CC)
GlaxoSmithKline
AHS Cancer Control Alberta
HealthPartners Institute
Valerio Therapeutics
Valerio Therapeutics